Regeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk

Dow Jones

2025/04/30

1404 ET - Regeneron missed analysts' 1Q sales and earnings targets, driven by a 26% decline in sales of Eylea, the company's blockbuster vision-loss drug. Doctors are opting for lower-cost alternatives, in part because of problems Medicare patients are having getting copay assistance from nonprofit foundations funded by the pharmaceutical industry. Regeneron is trying to get other drugmakers to match its donations to the foundations so their programs are better funded, CEO Leonard Schleifer tells analysts. Regeneron sinks 7%; the stock has fallen 36% over the past 12 months as the company adjusts to generic competition for Eylea. (joseph.walker@wsj.com)

(END) Dow Jones Newswires

April 29, 2025 14:04 ET (18:04 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2531767519"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531767519\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2531767519?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-30 02:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531767519","market":"fut","top_or_hot":-1,"title":"Regeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1404 ET - Regeneron missed analysts' 1Q sales and earnings targets, driven by a 26% decline in sales of Eylea, the company's blockbuster vision-loss drug. Doctors are opting for lower-cost alternatives, in part because of problems Medicare patients are having getting copay assistance from nonprofit foundations funded by the pharmaceutical industry. Regeneron is trying to get other drugmakers to match its donations to the foundations so their programs are better funded, CEO Leonard Schleifer tells analysts. Regeneron sinks 7%; the stock has fallen 36% over the past 12 months as the company adjusts to generic competition for Eylea. (joseph.walker@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2025 14:04 ET (18:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-30 02:04</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1404 ET - Regeneron missed analysts' 1Q sales and earnings targets, driven by a 26% decline in sales of Eylea, the company's blockbuster vision-loss drug. Doctors are opting for lower-cost alternatives, in part because of problems Medicare patients are having getting copay assistance from nonprofit foundations funded by the pharmaceutical industry. Regeneron is trying to get other drugmakers to match its donations to the foundations so their programs are better funded, CEO Leonard Schleifer tells analysts. Regeneron sinks 7%; the stock has fallen 36% over the past 12 months as the company adjusts to generic competition for Eylea. (joseph.walker@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2025 14:04 ET (18:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REGN","symbol_name":"再生元制药公司","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2531767519","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531767519","pubTimestamp":1745949840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1404 ET - Regeneron missed analysts' 1Q sales and earnings targets, driven by a 26% decline in sales of Eylea, the company's blockbuster vision-loss drug. Doctors are opting for lower-cost alternatives, in part because of problems Medicare patients are having getting copay assistance from nonprofit foundations funded by the pharmaceutical industry. Regeneron is trying to get other drugmakers to match its donations to the foundations so their programs are better funded, CEO Leonard Schleifer tells analysts. Regeneron sinks 7%; the stock has fallen 36% over the past 12 months as the company adjusts to generic competition for Eylea. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"REGN":"再生元制药公司"},"translate_title":"再生元(Regeneron)因主要眼科药物销量下滑而下滑——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":0.9},"content_text":"1404 ET - Regeneron missed analysts' 1Q sales and earnings targets, driven by a 26% decline in sales of Eylea, the company's blockbuster vision-loss drug. Doctors are opting for lower-cost alternatives, in part because of problems Medicare patients are having getting copay assistance from nonprofit foundations funded by the pharmaceutical industry. Regeneron is trying to get other drugmakers to match its donations to the foundations so their programs are better funded, CEO Leonard Schleifer tells analysts. Regeneron sinks 7%; the stock has fallen 36% over the past 12 months as the company adjusts to generic competition for Eylea. (joseph.walker@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  April 29, 2025 14:04 ET (18:04 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}